Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study
- PMID: 28103712
- DOI: 10.1176/appi.ajp.2016.16040442
Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study
Abstract
Objective: Diabetes mellitus contributes to excessive cardiovascular deaths and reduced life expectancy in schizophrenia. This population-based cohort study investigated the endogenous risk for diabetes in antipsychotic-naive schizophrenia and evaluated the risks added by starting antipsychotic treatment in people with schizophrenia.
Method: The study followed all people born in Denmark on or after Jan. 1, 1977, until Jan. 1, 2013 (N=2,736,510). The Danish Psychiatric Central Research Register ascertained schizophrenia diagnoses. The Danish National Prescription Registry provided data on prescriptions of antipsychotics. Diabetes was ascertained from the Danish National Patient Register and Danish National Prescription Registry. The authors estimated the endogenous and antipsychotic-related risks for diabetes by using Cox proportional hazards regression models, while accounting for potential confounders.
Results: Of the cohort members, 14,118 (0.52%) developed diabetes, and 8,945 (0.33%) developed schizophrenia during follow-up (49,582,279 person-years). The adjusted hazard ratio for diabetes was 3.07 (95% confidence interval [CI], 1.71-5.41) in antipsychotic-naive schizophrenia compared with the general population. The risk for diabetes after starting antipsychotic treatment was significantly higher (adjusted hazard ratio, 3.64; 95% CI, 1.95-6.82) than the risk in antipsychotic-naive schizophrenia, after adjustment for family history of diabetes and other potential confounders. First-line treatment with either first-generation antipsychotics (adjusted hazard ratio, 3.06; 95% CI, 1.32-7.05) or second-generation antipsychotics (adjusted hazard ratio, 3.44; 95% CI, 1.73-6.83) increased the risk for diabetes without a statistically significant difference. Appropriate sensitivity analyses limited to type 2 diabetes corroborated these results.
Conclusions: Schizophrenia confers a high endogenous risk for diabetes, and the risk is further increased by both first-generation and second-generation antipsychotics. Early detection and effective treatment of diabetes should be an integral part of multidisciplinary management of schizophrenia regardless of antipsychotic drug exposure.
Keywords: Antipsychotics; Diabetes; Drug Side Effects-Other; Epidemiology; Schizophrenia.
Comment in
-
Diabetes and Schizophrenia-New Findings for an Old Puzzle.Am J Psychiatry. 2017 Jul 1;174(7):616-617. doi: 10.1176/appi.ajp.2017.17040409. Am J Psychiatry. 2017. PMID: 28669214 No abstract available.
Similar articles
-
Antipsychotic exposure and infection risk in people with schizophrenia spectrum disorders during the COVID-19 pandemic: a Danish nationwide registry study.Lancet Psychiatry. 2024 Oct;11(10):796-806. doi: 10.1016/S2215-0366(24)00223-2. Epub 2024 Sep 3. Lancet Psychiatry. 2024. PMID: 39241794
-
Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study.JAMA Psychiatry. 2015 Jun;72(6):612-9. doi: 10.1001/jamapsychiatry.2015.0082. JAMA Psychiatry. 2015. PMID: 25875310 Free PMC article.
-
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.Neuropsychopharmacology. 2010 Aug;35(9):1997-2004. doi: 10.1038/npp.2010.78. Epub 2010 Jun 2. Neuropsychopharmacology. 2010. PMID: 20520598 Free PMC article.
-
[Schizophrenia, diabetes mellitus and antipsychotics].Encephale. 2004 Jul-Aug;30(4):382-91. doi: 10.1016/s0013-7006(04)95452-8. Encephale. 2004. PMID: 15538314 Review. French.
-
An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Hum Psychopharmacol. 2011. PMID: 23055416 Review.
Cited by
-
Temporally ordered associations between type 2 diabetes and brain disorders - a Danish register-based cohort study.BMC Psychiatry. 2022 Aug 26;22(1):573. doi: 10.1186/s12888-022-04163-z. BMC Psychiatry. 2022. PMID: 36028833 Free PMC article.
-
Diabetic ketoacidosis and diabetes associated with antipsychotic exposure among a previously diabetes-naive population with schizophrenia: a nationwide nested case-control study.Diabetologia. 2017 Sep;60(9):1678-1690. doi: 10.1007/s00125-017-4320-5. Epub 2017 Jun 7. Diabetologia. 2017. PMID: 28593353
-
Peripheral Lipid Signatures, Metabolic Dysfunction, and Pathophysiology in Schizophrenia Spectrum Disorders.Metabolites. 2024 Aug 28;14(9):475. doi: 10.3390/metabo14090475. Metabolites. 2024. PMID: 39330482 Free PMC article. Review.
-
Metabolic biomarkers of clinical outcomes in severe mental illness (METPSY): protocol for a prospective observational study in the Hub for metabolic psychiatry.BMC Psychiatry. 2025 Feb 13;25(1):122. doi: 10.1186/s12888-025-06579-9. BMC Psychiatry. 2025. PMID: 39948527 Free PMC article.
-
Glucose dysregulation in antipsychotic-naive first-episode psychosis: in silico exploration of gene expression signatures.Transl Psychiatry. 2024 Jan 10;14(1):19. doi: 10.1038/s41398-023-02716-8. Transl Psychiatry. 2024. PMID: 38199991 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical